Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

NCT04523571 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: BNT162b1
OTHER: Placebo

Sponsor

BioNTech SE

Collaborators

[object Object]